2 AI Healthcare Stocks to Buy Right Now

Tempus reported Q4 revenue of $367M, up 83% year-over-year, with analysts' consensus target of $77.93 implying roughly 70% upside from the current price. Recursion leverages ~50 petabytes (52.4M GB) of chemical/biological data, is partnering with Sanofi and Roche, and has begun receiving developmental milestone payments as it commercializes AI-driven virtual R&D. The AI-powered drug development market is cited to potentially grow ~30% annually through 2035; near-term market impact is stock-specific rather than market-wide.

Analysis

AI-first drug discovery and clinical decision platforms are creating a bifurcated competitive map: capital-efficient, recurring-revenue software/analytics (Tempus) versus capital-and-risk-heavy de-risking-as-a-service (Recursion). Tempus's revenue cadence and customer stickiness create an operational-leverage runway where modest margin improvement (5–10ppt) over 12–24 months could convert current growth into double-digit free cash flow, making valuation sensitive to a few quarters of outperformance. Recursion’s asset-side model carries binary clinical and milestone risk; its dataset and label quality are the real moat, but that moat is contestable if larger pharmas replicate labeling pipelines using their clinical trial data within 2–4 years.

Second-order effects: widespread adoption of in-silico pre-screening will compress demand for low-value wet-lab CRO work and accelerate spending toward cloud, compute, and high-throughput imaging vendors — beneficiaries include scale compute providers and niche sequencing/phenotyping tools, while mid-tier CROs face margin pressure. Regulators and payors will increasingly test provenance and explainability of model-driven claims; a regulatory tightening or a high-profile reproducibility failure could impose a months-long de-risking period where partnership payments are renegotiated.

Key catalysts and risks are tightly timed: partnership milestone windows and quarterly revenue beats for Tempus are 3–12 month catalysts, whereas meaningful derisking of Recursion’s internal pipeline is a 12–48 month event; a single failed clinical readout could repriced expectations by 30–70%. Market structure risk: investor appetite for AI-healthcare froth can reverse quickly if macro liquidity tightens, so position sizing and option structures matter more than buy-and-hold for these names.

Key Decisions for Investors

• Long TEM (core): initiate a 3–6% portfolio weight via 12–18 month horizon. Buy TEM shares or buy Jan-2027 LEAPS calls (e.g., strike ~ $60–80 depending on market) to capture 30–70% upside if revenue/margin cadence continues; size to cap potential loss at 10–12% of portfolio if growth stalls.
• Pair trade (defensive): long SNY 18–24 month (2–4% weight) / short RXRX (1–2% weight). Rationale: capture stable pharma optionality and insider ability to internalize AI vs small-cap execution and binary clinical risk; target asymmetric payoff of +20–40% vs -30% on the short leg if a clinical/milestone miss occurs.
• Event-driven RXRX speculation: if you want exposure to potential upside from partnership milestones, purchase out-of-the-money RXRX Jan-2027 calls sized as a small, disciplined catalyst bet (<1% portfolio). Limit aggregate exposure because a single negative readout or dilution event can exceed 50% downside.
• Hedge for headline/regulatory risk: buy protective put spreads on TEM/RXRX (3–6 month) sized to hedge 25–40% of exposure in case of sector-wide derating triggered by reproducibility or FDA guidance changes; cost-effective put spreads limit downside while preserving upside participation.